As of Thursday close, Recursion Pharmaceuticals Inc.’s (NASDAQ:RXRX) stock was up $0.08, moving up 0.92 percent to $8.78. The average number of shares traded per day over the past five days has been 4,774,480 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.20 fall in that time frame. In the last twenty days, the average volume was 5,354,440, while in the previous 50 days, it was 6,813,228.
Since last month, RXRX stock retreated -44.64%. Shares of the company fell to $8.42 on 08/17/23, the lowest level in the past month. A 52-week high of $16.75 was reached on 07/19/23 after having rallying from a 52-week low of $4.54. Since the beginning of this year, RXRX’s stock price has risen by 13.88% or $1.07, and marked a new high 14 times. However, the stock has declined by -47.57% since its 52-week high.
RXRX stock investors should be aware that Recursion Pharmaceuticals Inc. (RXRX) stock had its last reported insider trading activity 2 days ago on Aug 16. Secora Michael, the Chief Financial Officer of the company, disposed of 25,000 shares for $8.90 on Aug 16. It resulted in a $222,518 divestment by the insider. Secora Michael sold 25,000 shares at an average price of $9.27 on Aug 15. The insider now owns 850,686 shares following the transaction. On Aug 15, Chief Business Officer Virani Shafique sold 18,000 shares at $9.25 apiece. The transaction was valued at $166,500.
Valuation Metrics
The stock’s beta is 0.06. Besides these, the trailing price-to-sales (P/S) ratio of 35.23, the price-to-book (PB) ratio of 3.67.
Financial Health
In the three months ended June 29, Recursion Pharmaceuticals Inc.’s quick ratio stood at 3.80, while its current ratio was 3.80, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 3.80% percent. Based on annual data, RXRX earned -$8.43 million in gross profit and brought in $39.84 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -50.50%. Return on equity (ROE) for the past 12 months was -58.70%.
In Recursion Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $1.16 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. RXRX’s revenue rose 30.4% to $12.13 million during the quarter, while net income inched up to $11.02 million. While analysts expected Recursion Pharmaceuticals Inc. to report -$0.37 quarterly earnings, the actual figure was -$0.38 per share, beating the consensus estimate by -2.70%. During the quarter, the company generated -$76.17 million in EBITDA. The liabilities of Recursion Pharmaceuticals Inc. were 197.74 million at the end of its most recent quarter ended June 29, and its total debt was $52.9 million. The value of shareholders’ equity is $215.59 million.
Technical Picture
This quick technical analysis looks at Recursion Pharmaceuticals Inc.’s (RXRX) price momentum. With a historical volatility rate of 67.79%, the RSI 9-day stood at 27.38% on 17 August.
With respect to its five-day moving average, the current Recursion Pharmaceuticals Inc. price is down by -12.02% percent or -$1.20. At present, RXRX shares trade -40.72% below its 20-day simple moving average and +31.24% percent above its 100-day simple moving average. However, the stock is currently trading approximately +1.74% above its SMA50 and -20.83% below its SMA200.
Stochastic coefficient K was 4.88% and Stochastic coefficient D was 5.65%, while ATR was 1.01. Given the Stochastic reading of 6.07% for the 14-day period, the RSI (14) reading has been calculated as 36.24%. As of today, the MACD Oscillator reading stands at -1.01, while the 14-day reading stands at -2.18.
Analyst Ratings
Morgan Stanley launched its rating on Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) to an Equal-weight in a note to investors on May 22, 2023. Recursion Pharmaceuticals Inc. (RXRX) has been rated Overweight by analysts. According to 0 brokerage firms, RXRX is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Recursion Pharmaceuticals Inc. stock as buy, with 3 recommending it as overweight.
With a median target price of $12.50, the current consensus forecast for the stock is $9.00 – $35.00. Based on these forecasts, analysts predict Recursion Pharmaceuticals Inc. (RXRX) will achieve an average price target of $15.13.
